Yarrow Prices $150M Offering at $26, a 4.6% Discount to Last Close
YARW sits 92% above its 52-week low of $14.165.
Summary
Yarrow priced its underwritten public offering of 5.77 million shares at $26.00, a 4.6% discount to the last close of $27.25, raising approximately $150 million in gross proceeds. The deal includes a 30-day underwriters' option for up to 865,384 additional shares. This follows the company's announcement of the offering earlier today and comes after the VYNE Therapeutics merger and a recent Phase 2a/2b trial initiation for YB-101. The offering is highly dilutive relative to the company's $75.9 million market cap, but the modest discount suggests reasonable institutional demand. Proceeds will fund R&D and general corporate purposes. Closing is expected September 14, 2026.
At the time of this announcement, YARW was trading at $27.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.9M. The 52-week trading range was $14.17 to $46.95. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: BusinessWire.